ASCO Direct GU Highlights Meeting 2025

This event is over

Quickfacts

: February 21, 2025
: 16:00–19:30
: Landesmuseum Zurich
: English
: Oncology

Please save the date to join us in Switzerland on Friday, February 21, 2025 for the hybrid ASCO Direct™ GU Highlights Meeting.

Confirmed CME: SGU 3 | SSMO 3

Registration: https://medicinematters.com/asco-direct-gu-highlights-switzerland/

The ASCO Direct™ GU Highlights Meeting is an educational program containing selected original sessions from the 2025 ASCO Genitourinary Cancers Symposium on prostate, renal cell and urothelial cancer. You will have the opportunity to view the original sessions and discuss the clinical relevance and implications for Swiss treatment landscape of study outcomes with your colleagues.

We look forward to welcoming you at the ASCO Direct™ GU Highlights meeting 2025.

Your faculty

PD Dr. med. Aurelius Omlin and Prof. Dr. med. Arnoud Templeton

The ASCO Direct™ GU Highlights Meeting is an official ASCO Direct™ program and Springer Healthcare is the official local partner for this event. Please feel free to contact asco@springer.com if you have any questions.

ASCO DIRECT™ programs are officially licensed by the American Society of Clinical Oncology, Inc. (ASCO). Each presentation is provided solely for educational and informational purposes and personal use only. No part of any presentation may be edited or altered, or reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, nor may it be used for commercial purposes, without in each case the express written permission of ASCO. The ideas and opinions expressed in this presentation do not necessarily reflect those of ASCO. The mention of any company, product, service, or therapy does not constitute an endorsement of any kind by ASCO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify , among other matters, the dosage, the method and duration of administration, or contraindications. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this presentation or any errors or omissions. © 2024 American Society of Clinical Oncology, Inc. All rights reserved worldwide.

Landesmuseum Zürich, Museumstrasse 2, 8001 Zurich

Open Address in Maps

February 21, 2025

16:00 16:05	Introduction Aurelius Omlin, Arnoud Templeton
16:05 17:10	Prostate Cancer Nutrition: - A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial. - Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial. Radiation therapy and Surgey Updates: - Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials. - Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial. - Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs). mHSPC: - Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. mCRPC: - Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. - Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study. Aurelius Omlin, Thomas Hermanns, Alexandros Papachristofilou
17:10 18:10	Renal Cell Carcinoma Standard of care in mRCC: - Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial. - Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. mRCC - Looking to the future: - The Future of Biomarkers in Renal Cell Carcinoma - Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study. - Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study. - KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC). Katharina Reichel, Berna Özdemir
18:10 18:25	Break
18:25 19:25	Urothelial Carcinoma, Testicular and Miscellaneous Bladder Cancer Emerging new treatments: - Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. - Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma. - A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4). Updated game changers: - Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274. - Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. - EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). Testicular Cancer - Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results. Stefanie Fischer, Christian Fankhauser, Arnoud Templeton
19:25 19:30	Closing remarks Aurelius Omlin, Arnoud Templeton